surmount-1 tirzepatide trial obesity without diabetes after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 tirzepatide surmount once weekly for

These effects are often mild to moderate and tend to decrease over time

Zepbound carries a boxed warning regarding the risk of thyroid C-cell tumors and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

Transform your health journey and take the first step toward better weight management, improved blood sugar levels and a healthier lifestyle.

If you feel unusually cold after starting GLP-1 treatment, comfort measures such as layering clothing, drinking warm fluids and keeping active may help

2004;62(suppl 1):508

"It was dark and raised, about the size of a pea," she says